Citations (15)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Lidia Gazzola, Paola Cicconi, Diego Ripamonti, Elisa Di Filippo, Giulia Gustinetti, Antonio Di Biagio, Giulia Marchetti, Teresa Bini & Antonella d’Arminio Monforte. (2014) Efficacy and Safety of Darunavir/Ritonavir Plus Etravirine Dual Regimen in Antiretroviral Therapy–Experienced Patients: A Multicenter Clinical Experience. HIV Clinical Trials 15:4, pages 140-150.
Read now
Read now
Roberto Rossotti, Maria Cristina Moioli, Leonardo Chianura, Isabella Errante, Carloandrea Orcese, Maurizio Orso, Clara Schiantarelli, Irene Schlacht, Giovanna Travi, Beniamino Vigo, Maria Riccarda Villa, Alberto Volonterio & Massimo Puoti. (2012) Lamivudine or emtricitabine (XTC)/protease inhibitor dual therapy as a harm-reduction strategy in patients with tenofovir-related renal toxicity: A case–control study. Scandinavian Journal of Infectious Diseases 44:11, pages 879-883.
Read now
Read now
Articles from other publishers (13)
Salvatore Martini, Paolo Maggi, Cristina Gervasoni, Lorenzo Onorato, Sergio Ferrara, Loredana Alessio, Chiara Bellacosa, Vincenzo Esposito, Giovanni Di Filippo, Addolorata Masiello, Adelaide Maddaloni, Simona Madonia, Giovanna D’Alessio, Viviana Rizzo & Nicola Coppola. (2022) Dynamics of Lipid Profile in Antiretroviral-Naïve HIV-Infected Patients, Treated with TAF-Based Regimens: A Multicenter Observational Study. Biomedicines 10:12, pages 3164.
Crossref
Crossref
M Jaeckle, P Khaykin, A Haberl, P De Leuw, G Schüttfort, C Stephan & T Wolf. (2016) Efficacy of raltegravir-containing regimens in antiretroviral-naïve and -experienced individuals in routine clinical practice. International Journal of STD & AIDS 27:13, pages 1170-1179.
Crossref
Crossref
Giovanni Guaraldi, André Fragoso Gomes & Ana Rita Silva. 2016. Managing the Older Adult Patient with HIV. Managing the Older Adult Patient with HIV
129
180
.
Karen T. TashimaLaura M. SmeatonCarl J. FichtenbaumAdriana AndradeJoseph J. EronRajesh T. GandhiVictoria A. JohnsonKarin L. KlingmanJustin RitzSally HodderJorge L. SantanaTimothy WilkinRichard H. Haubrich. (2015) HIV Salvage Therapy Does Not Require Nucleoside Reverse Transcriptase Inhibitors. Annals of Internal Medicine 163:12, pages 908-917.
Crossref
Crossref
Amit C. Achhra, Mark A. Boyd, Matthew G. Law, Gail V. Matthews, Anthony D. Kelleher & David A. Cooper. (2014) Moving Away from Ritonavir, Abacavir, Tenofovir, and Efavirenz (RATE) - Agents That Concern Prescribers and Patients: A Feasibility Study and Call for a Trial. PLoS ONE 9:6, pages e99530.
Crossref
Crossref
Amit C Achhra & Mark A Boyd. (2013) Antiretroviral regimens sparing agents from the nucleoside(tide) reverse transcriptase inhibitor class: a review of the recent literature. AIDS Research and Therapy 10:1, pages 33.
Crossref
Crossref
J. Burgos, M. Crespo, V. Falco, A. Curran, J. Navarro, A. Imaz, P. Domingo, D. Podzamczer, M. G. Mateo, S. Villar, E. Van den Eynde, E. Ribera & A. Pahissa. (2012) Simplification to dual antiretroviral therapy including a ritonavir-boosted protease inhibitor in treatment-experienced HIV-1-infected patients. Journal of Antimicrobial Chemotherapy 67:10, pages 2479-2486.
Crossref
Crossref
Dario Cattaneo, Diego Ripamonti, Cristina Gervasoni, Simona Landonio, Paola Meraviglia, Sara Baldelli, Valeria Cozzi, Serena Fucile & Emilio Clementi. (2012) Limited Sampling Strategies for the Estimation of Raltegravir Daily Exposure in HIV-Infected Patients. The Journal of Clinical Pharmacology 52:3, pages 440-445.
Crossref
Crossref
Edward M. Gardner, Andre G. Melendez, Maria Astiz & Kimberly Bray. (2011) Adherence and Preexisting Major Protease Inhibitor Resistance Mutations are Associated with Virologic Failure of a Dual-Class Antiretroviral Regimen with Inhibitors of HIV-1 Viral Protease and Integrase. Journal of the International Association of Physicians in AIDS Care 11:1, pages 34-39.
Crossref
Crossref
Robyn Teply, Mark GoodmanChristopher J. Destache. (2011) Lopinavir/Ritonavir: A Review for 2011. Clinical Medicine Insights: Therapeutics 3, pages CMT.S2018.
Crossref
Crossref
Dario Cattaneo, Diego Ripamonti, Sara Baldelli, Valeria Cozzi, Francesca Conti & Emilio Clementi. (2010) Exposure-Related Effects of Atazanavir on the Pharmacokinetics of Raltegravir in HIV-1-Infected Patients. Therapeutic Drug Monitoring 32:6, pages 782-786.
Crossref
Crossref
Jade Ghosn, Giampiero Carosi, Santiago Moreno, Vadim Pokrovsky, Adriano Lazzarin, Gilles Pialoux, Jose Sanz-Moreno, Agnes Balogh, Eric Vandeloise, Sophie Biguenet, Ghislaine Leleu & Jean-Francois Delfraissy. (2010) Unboosted atazanavir-based therapy maintains control of HIV type-1 replication as effectively as a ritonavir-boosted regimen. Antiviral Therapy 15:7, pages 993-1002.
Crossref
Crossref
. (2010) Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety 19:6, pages i-xiii.
Crossref
Crossref